We Offer Worldwide Shipping
Login Wishlist

Alphalipoic acid

$43

  • Brand : BIOFRON

  • Catalogue Number : BF-A3007

  • Specification : 98%

  • CAS number : 1077-28-7

  • Formula : C8H14O2S2

  • Molecular Weight : 206.33

  • Volume : 100mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-A3007

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

206.33

Appearance

Powder

Botanical Source

Structure Type

Others

Category

SMILES

C1CSSC1CCCCC(=O)O

Synonyms

IUPAC Name

Density

1.2±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

173.0±19.3 °C

Boiling Point

362.5±11.0 °C at 760 mmHg

Melting Point

60-62ºC

InChl

InChI=1S/C8H14O2S2/c9-8(10)4-2-1-3-7-5-6-11-12-7/h7H,1-6H2,(H,9,10)

InChl Key

AGBQKNBQESQNJD-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

2934990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:1077-28-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

28497636

Title

Contact allergy to thioctic acid present in Hypromellose ® eye drops

Author

Sarah Craig 1, Rachel Urwin 1, Mark Wilkinson 1

Publish date

2017 Jun;

PMID

26899808

Title

Further evidence of thioctic acid (α-lipoic acid) being a strong cosmetic sensitizer

Author

Julie Leysen 1, Olivier Aerts 1

Publish date

2016 Mar

PMID

19338137

Abstract

Morphine (CAS 57-27-2) administration or its removal induces alterations in glucose levels and oxidative status or behaviour signs, which may be hypothetically closely related; if this is correct, controlling glucose changes may lead to modifications in peroxide levels and in behaviour profile. It therefore seems important to find a drug able to control alterations of glucose metabolism, peroxide generation and behaviour symptoms in morphine or morphine withdrawal animals. This paper describes the effects of morphine or morphine plus naloxone (CAS 51481-60-8) on the plasma levels of glucose, malondialdehyde (MDA) (CAS 100683-54-3) and behavioural signs in rats treated or not with alpha-lipoic acid (CAS 1077-28-7), known to interfere with glucose and peroxide levels. The administration of morphine or its removal by naloxone alters plasma glucose levels, increases MDA values, and also affects signs such as pain threshold values, fecal excretion and jumping behaviour. The injection of alpha-lipoic acid decreases glycemia in rats treated with morphine or morphine plus naloxone. This result may be due to the capacity of alpha-lipoic acid to facilitate glucose transport and its utilization. The administration of a-lipoic acid to rats given morphine or morphine plus naloxone lowers total MDA levels because of its peroxide scavenging capacity. In animals injected with morphine plus naloxone, which show altered pain thresholds, high fecal excretion and jumping behaviour, treatment with alpha-lipoic acid increases latency times, decreases fecal excretion and reduces jumping. These effects can be attributed to the capacity of alpha-lipoic acid to interfere with mediators or peroxides involved in the modified behaviour. The glycemia levels, MDA values and behavioural signs seem to be interconnected in the reported experiments. The administration of alpha-lipoic acid is demonstrated to control the alterations in plasma glucose levels, peroxide values or behavioural profile in animals receiving morphine or morphine plus naloxone.

Title

Effects of alpha-lipoic acid administration on plasma glucose levels, total malondialdehyde values and withdrawal signs in rats treated with morphine or morphine plus naloxone

Author

Arnaldo Pinelli 1, Giuliana Cighetti, Silvio Trivulzio

Publish date

2009


Description :

Empty ...